The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
The role of CD95 and CD95 ligand in cancer
Open accessAbstract
CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liu, Q., Tan, Q., Zheng, Y., Chen, K., Qian, C., Li, N., Wang, Q., & Cao, X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.525014 · Cited by 33
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.054 · Cited by 1,910
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Kägi, D., Ledermann, B., Bürki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,757
CD95's deadly mission in the immune system
Krammer, P. H. (2000) · Nature · doi:10.1038/35037728 · Cited by 1,717
Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Cancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287
Induction of Apoptosis by Cancer Chemotherapy
Kaufmann, S. H., & Earnshaw, W. C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4838 · Cited by 1,266
Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells
Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., Qian, D., Diehn, M., Liu, H., Panula, S. P., Chiao, E., et al. (2009) · Cell · doi:10.1016/j.cell.2009.07.011 · Cited by 1,213
FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
Medema, J. P. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2794 · Cited by 1,188
The CD95(APO-1/Fas) DISC and beyond
Peter, M. E., & Krammer, P. H. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401186 · Cited by 1,080
Self-citationCytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
The many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., & Kidd, V. J. (2000) · Nature Medicine · doi:10.1038/75007 · Cited by 811
Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity.
Rouvier, E., Luciani, M. F., & Golstein, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.195 · Cited by 787
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., et al. (1996) · Nature Medicine · doi:10.1038/nm0396-317 · Cited by 666
Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations
Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K.-M., Johnson, M., Lynch, D., Tsien, R. Y., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2354 · Cited by 662
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005) · Nature Medicine · doi:10.1038/nm1173 · Cited by 604
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Fas transduces activation signals in normal human T lymphocytes.
Alderson, M. R., Armitage, R. J., Maraskovsky, E., Tough, T. W., Roux, E., Schooley, K., Ramsdell, F., & Lynch, D. H. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2231 · Cited by 521
Caspase Activation Is Required for T Cell Proliferation
Kennedy, N. J., Kataoka, T., Tschopp, J., & Budd, R. C. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1891 · Cited by 459
Let-7 expression defines two differentiation stages of cancer
Shell, S., Park, S.-M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., Feig, C., Lengyel, E., & Peter, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704372104 · Cited by 458
Self-citationThe Transcriptome Profile of Human Embryonic Stem Cells as Defined by SAGE
Richards, M., Tan, S., Tan, J., Chan, W., & Bongso, A. (2004) · STEM CELLS · doi:10.1634/stemcells.22-1-51 · Cited by 435
Fulda, S., Küfer, M. U., Meyer, E., van Valen, F., Dockhorn-Dworniczak, B., & Debatin, K.-M. (2001) · Oncogene · doi:10.1038/sj.onc.1204750 · Cited by 404
Barth, R. J., Mulé, J. J., Spiess, P. J., & Rosenberg, S. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.647 · Cited by 402
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis
O’ Reilly, L. A., Tai, L., Lee, L., Kruse, E. A., Grabow, S., Fairlie, W. D., Haynes, N. M., Tarlinton, D. M., Zhang, J.-G., Belz, G. T., et al. (2009) · Nature · doi:10.1038/nature08402 · Cited by 400
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396
The CD95 Receptor: Apoptosis Revisited
Peter, M. E., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A.-O., Newell, M. K., Owen, L. B., Pope, R. M., Tschopp, J., Wajant, H., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.031 · Cited by 395
Self-citationMolecular Ordering of the Initial Signaling Events of CD95
Algeciras-Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., & Peter, M. E. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.207-220.2002 · Cited by 393
Self-citationAlam, A., Cohen, L. Y., Aouad, S., & Sékaly, R.-P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1879 · Cited by 390
Chen, L., Park, S.-M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., Turner, J. R., Fu, Y.-X., Romero, I. L., Lengyel, E., et al. (2010) · Nature · doi:10.1038/nature09075 · Cited by 378
Self-citationTargeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver
Adachi, M., Suematsu, S., Kondo, T., Ogasawara, J., Tanaka, T., Yoshida, N., & Nagata, S. (1995) · Nature Genetics · doi:10.1038/ng1195-294 · Cited by 374
Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
Stalder, T., Hahn, S., & Erb, P. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.3.1127 · Cited by 373
Fas engagement induces neurite growth through ERK activation and p35 upregulation
Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J.-S., & Newell, M. K. (2003) · Nature Cell Biology · doi:10.1038/ncb916 · Cited by 312
Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma
Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.003 · Cited by 309
Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H., & Tschopp, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.657 · Cited by 297
Ju, S. T., Cui, H., Panka, D. J., Ettinger, R., & Marshak-Rothstein, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4185 · Cited by 296
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
Kojima, H., Shinohara, N., Hanaoka, S., Someya-Shirota, Y., Takagaki, Y., Ohno, H., Saito, T., Katayama, T., Yagita, H., Okumura, K., et al. (1994) · Immunity · doi:10.1016/1074-7613(94)90066-3 · Cited by 290
CD95 ligand induces motility and invasiveness of apoptosis‐resistant tumor cells
Barnhart, B. C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., & Peter, M. E. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600325 · Cited by 284
Self-citationActivated T Cell Exosomes Promote Tumor Invasion via Fas Signaling Pathway
Cai, Z., Yang, F., Yu, L., Yu, Z., Jiang, L., Wang, Q., Yang, Y., Wang, L., Cao, X., & Wang, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103466 · Cited by 265
Fas engagement accelerates liver regeneration after partial hepatectomy
Desbarats, J., & Newell, M. K. (2000) · Nature Medicine · doi:10.1038/78688 · Cited by 241
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 235
Cytotoxic drugs and the CD95 pathway
Friesen, C., Fulda, S., & Debatin, K.-M. (1999) · Leukemia · doi:10.1038/sj.leu.2401333 · Cited by 208
GENETIC DISORDERS OF PROGRAMMED CELL DEATH IN THE IMMUNE SYSTEM
Bidère, N., Su, H. C., & Lenardo, M. J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090513 · Cited by 197
Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00072-2 · Cited by 191
mir-200c Regulates Induction of Apoptosis through CD95 by Targeting FAP-1
Schickel, R., Park, S.-M., Murmann, A. E., & Peter, M. E. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.018 · Cited by 167
Self-citationPlasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis
Bajou, K., Peng, H., Laug, W. E., Maillard, C., Noel, A., Foidart, J. M., Martial, J. A., & DeClerck, Y. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.012 · Cited by 161
T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm, W., Thoma, S. J., Leithäuser, F., Mӧller, P., Schirmbeck, R., & Reimann, J. (1998) · PubMed · Cited by 150
Hoogwater, F. J. H., Nijkamp, M. W., Smakman, N., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.046 · Cited by 147
Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams, V. M., Chavez, S. L., Kamsteeg, M., Hanczaruk, B., Schwartz, P. E., Rutherford, T., & Mor, G. (2003) · PubMed · Cited by 139
Breast cancer stem cells: tools and models to rely on
Charafe‐Jauffret, E., Ginestier, C., & Birnbaum, D. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-202 · Cited by 138
Wigginton, J. M., Gruys, E., Geiselhart, L., Subleski, J. J., Komschlies, K. L., Park, J., Wiltrout, T. A., Nagashima, K., Back, T. C., & Wiltrout, R. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10128 · Cited by 136
The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway
Tauzin, S., Chaigne-Delalande, B., Selva, É., Khadra, N., Daburon, S., Contin‐Bordes, C., Blanco, P., Seyec, J. L., Ducret, T., Counillon, L., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001090 · Cited by 132
Corsini, N. S., Sancho-Martinez, I., Laudenklos, S., Glagow, D., Kumar, S., Letellier, E., Koch, P., Teodorczyk, M., Kleber, S., Klussmann, S., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.004 · Cited by 129
Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801548 · Cited by 124
T Cell-Mediated, IFN-γ-Facilitated Rejection of Murine B16 Melanomas
Böhm, W., Thoma, S. J., Leithäuser, F., Mӧller, P., Schirmbeck, R., & Reimann, J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.897 · Cited by 122
Two CD95 tumor classes with different sensitivities to antitumor drugs
Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., & Peter, M. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2034995100 · Cited by 118
Self-citationControl of neuronal branching by the death receptor CD95 (Fas/Apo-1)
Zuliani, C., Kleber, S., Klussmann, S., Wenger, T., Kenzelmann, M., Schreglmann, N., Martinez, A., del Rio, J. A., Soriano, E., Vodrazka, P., et al. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401720 · Cited by 117
Malleter, M., Tauzin, S., Bessede, A., Castellano, R., Goubard, A., Godey, F., Lévêque, J., Jézéquel, P., Campion, L., Campone, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1794 · Cited by 114
FAP-1 Association with Fas (Apo-1) Inhibits Fas Expression on the Cell Surface
Ivanov, V. N., Lopez‐Bergami, P., Maulit, G., Sato, T., Sassoon, D. A., & Ronai, Z. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.10.3623-3635.2003 · Cited by 111
Induction of apoptosis and activation of NF‐κB by CD95 require different signalling thresholds
Legembre, P., Barnhart, B. C., Zheng, L., Vijayan, S., Straus, S. E., Puck, J. M., Dale, J. K., Lenardo, M. J., & Peter, M. E. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400280 · Cited by 108
Self-citationDoes CD95 have tumor promoting activities?
Peter, M. E., Legembre, P., & Barnhart, B. C. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.01.001 · Cited by 103
Self-citationTumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98
CD95 and TRAF2 promote invasiveness of pancreatic cancer cells
Trauzold, A., Röder, C., Sipos, B., Karsten, K., Arlt, A., Jiang, P., Martín-Subero, J. I., Siegmund, D., Müerköster, S. S., Raluy, L. P., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2984fje · Cited by 96
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Karl, I., Jossberger-Werner, M., Schmidt, N., Horn, S., Goebeler, M., Leverkus, M., Wajant, H., & Giner, T. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.404 · Cited by 93
CD95 and CD95L promote and protect cancer stem cells
Ceppi, P., Hadji, A., Kohlhapp, F. J., Pattanayak, A., Hau, A., Liu, X., Liu, H., Murmann, A. E., & Peter, M. E. (2014) · Nature Communications · doi:10.1038/ncomms6238 · Cited by 89
Self-citationThe Fas/Fas‐ligand system: a mechanism for immune evasion in human breast carcinomas
Gutierrez, L. S., Eliza, M., Niven‐Fairchild, T., Naftolin, F. N., & Mor, G. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006102601215 · Cited by 89
Zheng, H., Li, W., Wang, Y., Liu, Z., Cai, Y., Xie, T., Shi, M. Q., Wang, Z., & Jiang, B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.014 · Cited by 86
Prévost‐Blondel, A., Roth, E., Rosenthal, F. M., & Pircher, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3645 · Cited by 85
Winter, H., Hu, H., Urba, W. J., & Fox, B. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4462 · Cited by 82
Mann, B., Gratchev, A. N., Böhm, C., Hanski, M. L., Foss, H., Demel, G., Trojaneck, B., Schmidt‐Wolf, I. G. H., Stein, H. J., Riecken, E. O., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690202 · Cited by 82
Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita, M., Tachibana, M., Dhar, D. K., Kotoh, T., Kinugasa, S., Kubota, H., Masunaga, R., & Nagasue, N. (1999) · PubMed · Cited by 82
Death Induced by CD95 or CD95 Ligand Elimination
Hadji, A., Ceppi, P., Murmann, A. E., Brockway, S., Pattanayak, A., Bhinder, B., Hau, A., Chant, S. D., Parimi, V., Kolesza, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.035 · Cited by 80
Self-citationKarray, S., Kress, C., Cuvellier, S., Hue-Beauvais, C., Damotte, D., Babinet, C., & Lévi‐Strauss, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2118 · Cited by 79
Song, E., Chen, J., Ouyang, N., Su, F., Wang, M., & Heemann, U. W. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6692042 · Cited by 77
Ivanov, V. N., Ronai, Z. A., & Hei, T. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509866200 · Cited by 77
Nakamoto, Y., Kaneko, S., Fan, H. S., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020633 · Cited by 77
Munakata, S., Enomoto, T., Tsujimoto, M., Otsuki, Y., Miwa, H., Kanno, H., & Langrish, V. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1073 · Cited by 75
Shed Membrane Fragment-Associated Markers for Endometrial and Ovarian Cancers
Taylor, D. D., Lyons, K. S., & Gerçel-Taylor, Ç. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6551 · Cited by 74
Intratumoral T Cell Subset Ratios and Fas Ligand Expression on Brain Tumor Endothelium
Yu, J. S., Lee, P. K., Ehtesham, M., Samoto, K., Black, K. L., & Wheeler, C. J. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02700020 · Cited by 73
Legembre, P., Schickel, R., Barnhart, B. C., & Peter, M. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404334200 · Cited by 73
Self-citationCD95 in cancer: tool or target?
Martín-Villalba, A., Llorens-Bobadilla, E., & Wollny, D. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.002 · Cited by 70
Zheng, H., Cai, Y. D., Wang, Y. D., Cui, X., Xie, T., Li, W. J., Peng, L., Zhang, Y., Wang, Z. Q., Wang, J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.126 · Cited by 69
T cell-tumor cell: a fatal interaction?
Chappell, D. B., & Restifo, N. P. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050505 · Cited by 68
Tourneur, L., Mistou, S., Michiels, F.-M., Devauchelle‐Pensec, V., Rénia, L., Feunteun, J., & Chiocchia, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206399 · Cited by 67
Nijkamp, M. W., Hoogwater, F. J. H., Steller, E. J. A., Westendorp, B. F., van der Meulen, T. A., Leenders, M. W. H., Rinkes, I. H. M. B., & Kranenburg, O. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.040 · Cited by 63
CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
Teodorczyk, M., Kleber, S., Wollny, D., Sefrin, J. P., Aykut, B., Mateos, Á., Herhaus, P., Sancho-Martinez, I., Hill, O., Gieffers, C., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.217 · Cited by 61
Zheng, H., Li, W., Wang, Y., Xie, T., Cai, Y., Wang, Z., & Jiang, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt274 · Cited by 60
Sträter, J., Hinz, U., Hasel, C., Bhanot, U. K., Mechtersheimer, G., Lehnert, T., & Möller, P. (2005) · Gut · doi:10.1136/gut.2004.052696 · Cited by 59
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Volm, M., Koomägi, R., Mattern, J., & Efferth, T. (2002) · PubMed · Cited by 59
The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion
Steller, E. J. A., Ritsma, L., Raats, D., Hoogwater, F. J. H., Emmink, B. L., Govaert, K. M., Laoukili, J., Rinkes, I. H. M. B., van Rheenen, J., & Kranenburg, O. (2011) · EMBO Reports · doi:10.1038/embor.2011.129 · Cited by 58
Human and Mouse Colon Cancer Utilizes CD95 Signaling for Local Growth and Metastatic Spread to Liver
Li, H., Fan, X., Stoicov, C., Liu, J. H., Zubair, S., Tsai, E., Marie, R. S., Wang, T. C., Lyle, S. R., Kurt‐Jones, E. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.004 · Cited by 57
A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity
Ichikawa, K., Yoshida-Kato, H., Ohtsuki, M., Ohsumi, J., Yamaguchi, J., Takahashi, S., Tani, Y., Watanabe, M., Shiraishi, A., Nishioka, K., et al. (2000) · International Immunology · doi:10.1093/intimm/12.4.555 · Cited by 55
Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation
Mitsiades, C. S., Poulaki, V., Fanourakis, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2493 · Cited by 55
Yuan, K., Gu, J., Chen, J., Liu, H., Zhang, K., Li, Y., Wu, H., McDonald, J. M., & Chen, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202804 · Cited by 54
von Bernstorff, W., Glickman, J. N., Odze, R. D., Farraye, F. A., Joo, H. G., Goedegebuure, P. S., & Eberlein, T. J. (2002) · Cancer · doi:10.1002/cncr.10549 · Cited by 52
CD95 Ligand Is a Proliferative and Antiapoptotic Signal in Quiescent Hepatic Stellate Cells
Reinehr, R., Sommerfeld, A., & Häussinger, D. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.021 · Cited by 52
Autoimmunity in Mice Bearing lprcs: A Novel Mutant Gene
Kimura, M., & Matsuzawa, A. (1994) · International Reviews of Immunology · doi:10.3109/08830189409061727 · Cited by 44
Jarad, G., Wang, B., Khan, S., Devore, J., Miao, H., Wu, K. L., Nishimura, S. L., Wible, B. A., Konieczkowski, M., Sedor, J. R., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204901200 · Cited by 41
Chopin, D. K., Barei-Moniri, R., Maillé, P., Frère‐Belda, M. L., Muscatelli‐Groux, B., Merendino, N., Lecerf, L., Stoppacciaro, A., & Velotti, F. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63910-7 · Cited by 38
CD95 Is Part of a Let-7/p53/miR-34 Regulatory Network
Hau, A., Ceppi, P., & Peter, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049636 · Cited by 36
Self-citationPrognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma
Chatzitolios, A., Venizelos, I., Tripsiannis, G. A., Anastassopoulos, G. C., & Papadopoulos, N. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0945-x · Cited by 35
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer
Lee, J. K., Sayers, T. J., Back, T. C., et al. (2003) · APOPTOSIS · doi:10.1023/a:1022918625509 · Cited by 34
Fas Ligand Expression Is Correlated with Metastasis in Colorectal Carcinoma
Nozoe, T., Yasuda, M., Honda, M., Inutsuka, S., & Korenaga, D. (2003) · Oncology · doi:10.1159/000071208 · Cited by 34
Kojima, Y., Tsurumi, H., Goto, N., Shimizu, M., Kasahara, S., Yamada, T., Kanemura, N., Hara, T., Sawada, M., Saio, M., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00631.x · Cited by 34
Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege
Zhang, W. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i23.3632 · Cited by 30
Tumor promoting effects of CD95 signaling in chemoresistant cells
Ametller, E., García‐Recio, S., Costamagna, D., Mayordomo, C., Fernández‐Nogueira, P., Carbó, N., Pastor‐Arroyo, E. M., Gascón, P., & Almendro, V. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-161 · Cited by 29
Osaki, M., Kase, S., Kodani, I., Watanabe, M., Adachi, H., & Ito, H. (2001) · Gastric Cancer · doi:10.1007/s10120-001-8010-z · Cited by 28
Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack
Kowalczyk, D. W., Wlazlo, A. P., Giles‐Davis, W., Kammer, A. R., Mukhopadhyay, S., & Ertl, H. C. J. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700653 · Cited by 25
FAS/FASL Expression Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Oral Cavity
de Carvalho-Neto, P. B., dos Santos, M., de Carvalho, M. B., Mercante, A. M. D. C., dos Santos, V. P. P., Severino, P., Tajara, E. H., Louro, I. D., & da Silva, A. M. Á. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069024 · Cited by 25
CD95 is cytoprotective for intestinal epithelial cells in colitis
Park, S.-M., Chen, L., Zhang, M., Ashton‐Rickardt, P. G., Turner, J. R., & Peter, M. E. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21195 · Cited by 25
Self-citationLin, H.-C., Lai, P.-Y., Lin, Y.-P., Huang, J.-Y., & Yang, B.-C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.326058 · Cited by 23
Sf, W., Zhang, J.-W., Qian, W.-Y., et al. (2012) · PubMed · Cited by 23
Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas
Macher‐Goeppinger, S., Bermejo, J. L., Wagener, N., Hohenfellner, M., Haferkamp, A., Schirmacher, P., & Roth, W. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.005 · Cited by 22
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer
Owonikoko, T. K., Hossain, M. S., Bhimani, C., Chen, Z., Kim, S., Ramalingam, S. S., Sun, S., Shin, D. M., Waller, E. K., & Khuri, F. R. (2013) · Cancer · doi:10.1002/cncr.27937 · Cited by 21
Sejima, T., Morizane, S., Hinata, N., Yao, A., Isoyama, T., Saito, M., & Takenaka, A. (2012) · Urologia Internationalis · doi:10.1159/000334453 · Cited by 21
Chaudhry, P., Srinivasan, R., Patel, F. D., Gopalan, S., & Majumdar, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.23213 · Cited by 17
CD95L/FasL and its receptor CD95 (APO-1/Fas)
Peter, M. E., Barnhart, B. C., & Algeciras-Schimnich, A. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50042-9 · Cited by 16
Self-citationEser, B., Sarı, İ., Canöz, Ö., Altuntaş, F., Çakmak, E., Öztürk, A., Özkan, M., Er, O. S., Çetın, M., & Ünal, A. (2006) · American Journal of Hematology · doi:10.1002/ajh.20564 · Cited by 13
CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia
Park, S.-M., Rajapaksha, T. W., Zhang, M., Sattar, H. A., Fichera, A., Ashton‐Rickardt, P. G., & Peter, M. E. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0149-6 · Cited by 13
Self-citationSaigusa, S., Tanaka, K., Ohi, M., Toiyama, Y., Yasuda, H., Kitajima, T., Okugawa, Y., Inoue, Y., Mohri, Y., & Kusunoki, M. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.431 · Cited by 11
DICE: A novel tumor surveillance mechanism—a new therapy for cancer?
Peter, M. E. (2014) · Cell Cycle · doi:10.4161/cc.28673 · Cited by 10
Self-citationHoogwater, F. J. H., Snoeren, N., Nijkamp, M. W., Gunning, A. C., van Houdt, W. J., de Bruijn, M. T., Voest, E. E., van Hillegersberg, R., Kranenburg, O., & Rinkes, I. H. M. B. (2011) · PubMed · Cited by 8
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
Apoptosis and Clearance of Apoptotic Cells
Nagata, S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053010 · Cited by 1,103
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy
Mortezaee, K., Salehi, E., Mirtavoos‐mahyari, H., Motevaseli, E., Najafi, M., Farhood, B., Rosengren, R. J., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28122 · Cited by 340
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Metadata
- Authors
- Peter, M. E., Hadji, A., Murmann, A. E., Brockway, S., Putzbach, W., Pattanayak, A., & Ceppi, P.
- Venue
- Cell Death & Differentiation
- Published
- 2015-02-06
- Volume
- 22
- Issue
- 4
- Pages
- 549-559
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1971873029
- Cited by
- 357
- References
- 145
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.